PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update

PolyPid Ltd. (NASDAQ:PYPD) saw a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 8,900 shares, an increase of 111.9% from the August 15th total of 4,200 shares. Based on an average daily trading volume, of 6,700 shares, the days-to-cover ratio is presently 1.3 days. Approximately 0.2% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of PolyPid in a report on Thursday, August 15th.

PolyPid Stock Performance

PolyPid stock traded down $0.12 during trading on Friday, reaching $3.47. The company had a trading volume of 5,879 shares, compared to its average volume of 6,186. The firm’s 50-day simple moving average is $3.57 and its 200 day simple moving average is $4.26. PolyPid has a 52 week low of $2.95 and a 52 week high of $9.20. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 1.95. The firm has a market capitalization of $16.62 million, a price-to-earnings ratio of -0.27 and a beta of 1.32.

PolyPid (NASDAQ:PYPD) last issued its earnings results on Wednesday, August 14th. The company reported ($1.25) earnings per share for the quarter, topping the consensus estimate of ($1.51) by $0.26. Sell-side analysts forecast that PolyPid will post -4.39 earnings per share for the current fiscal year.

Institutional Trading of PolyPid

An institutional investor recently bought a new position in PolyPid stock. Rosalind Advisors Inc. acquired a new position in shares of PolyPid Ltd. (NASDAQ:PYPD) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 415,800 shares of the company’s stock, valued at approximately $1,913,000. PolyPid comprises about 1.8% of Rosalind Advisors Inc.’s portfolio, making the stock its 20th biggest position. Rosalind Advisors Inc. owned about 8.67% of PolyPid as of its most recent SEC filing. Hedge funds and other institutional investors own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.